Decreased infiltration of macrophage scavenger receptor-positive cells in initial negative biopsy specimens is correlated with positive repeat biopsies of the prostate.
Macrophage scavenger receptor (MSR)-positive inflammatory cells and tumor-associated macrophages (TAMs) have been reported to regulate the growth of various cancers. In this study, the infiltration of MSR-positive cells and TAMs was analyzed to predict the outcome of repeat biopsy in men diagnosed as having no malignancy at the first prostate biopsy. Repeat biopsy of the prostate was carried out in 92 patients who were diagnosed as having no malignancy at the first biopsy. Of these, 30 patients (32.6%) were positive for prostate cancer at the repeat biopsy. Tumor-associated macrophages and MSR-positive cells were immunohistochemically stained with mAbs CD68 and CD204, respectively. Six ocular measuring fields were chosen randomly under a microscope at x400 power in the initial negative biopsy specimens, and the mean TAM and MSR counts for each case were determined. No difference in TAM count was found between the cases with or without prostate cancer. By contrast, the MSR count in patients with cancer was significantly lower than that in patients without cancer at the repeat biopsy (P < 0.001). Logistic regression analysis indicated that the MSR count at first biopsy is a significantly better predictive factor for positive repeat biopsy than PSA velocity, interval between first and repeat biopsies, or TAM count. Decreased infiltration of MSR-positive cells in negative first biopsy specimens was correlated with positive findings in the repeat biopsy. The MSR count might be a good indicator for avoiding unnecessary repeat biopsies.
Nonomura
Norio
N
Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan. nono@uro.med.osaka-u.ac.jp
Takayama
Hitoshi
H
Kawashima
Atsunari
A
Mukai
Masatoshi
M
Nagahara
Akira
A
Nakai
Yasutomo
Y
Nakayama
Masashi
M
Tsujimura
Akira
A
Nishimura
Kazuo
K
Aozasa
Katsuyuki
K
Okuyama
Akihiko
A
D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D051117:Scavenger Receptors, Class A / Q000032:analysis / Q000502:physiology*; D012680:Sensitivity and Specificity
C495139:MSR1 protein, human; D051117:Scavenger Receptors, Class A; D017430:Prostate-Specific Antigen
Exp Mol Pathol. 2004 Oct;77(2):153-9
15351240
Urology. 2002 Nov;60(5):836-40
12429311
Carcinogenesis. 2005 Jul;26(7):1170-81
15498784
J Biol Chem. 1998 Jan 16;273(3):1562-7
9430696
Cancer. 2008 Dec 1;113(11):3075-99
18823041
J Natl Cancer Inst. 1998 Nov 4;90(21):1648-53
9811314
Eur Urol. 2007 Sep;52(3):639-41
17451871
J Urol. 1994 Nov;152(5 Pt 1):1358-68
7523702
J Urol. 2000 Mar;163(3):813-8
10687983
Clin Radiol. 2006 Feb;61(2):142-53
16439219
Urol Oncol. 2007 May-Jun;25(3):250-9
17483024
J Cancer Res Clin Oncol. 2004 Apr;130(4):217-21
14749923
Nat Rev Cancer. 2007 Apr;7(4):256-69
17384581
J Pathol. 2008 Sep;216(1):15-24
18553315
Eur J Cancer. 2006 Apr;42(6):717-27
16520032
Pathol Int. 2009 May;59(5):300-5
19432671
Prostate. 1998 Sep 15;37(1):19-29
9721065
Eur Urol. 2008 Nov;54(5):1081-8
18602209
BJU Int. 2007 Oct;100(4):733-7
17662075
J Urol. 2008 Jul;180(1):146-9
18485383
Semin Cancer Biol. 1991 Jun;2(3):189-95
1912527
Nature. 2002 Dec 19-26;420(6917):860-7
12490959
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Urology. 2007 Mar;69(3):532-5
17382159
J Urol. 2000 Apr;163(4):1144-8; discussion 1148-9
10737484
Clin Cancer Res. 2003 Jul;9(7):2673-7
12855646
BJU Int. 2009 Feb;103(4):470-4
18778349
J Urol. 2003 Oct;170(4 Pt 1):1184-8; discussion 1188
14501721
Nat Genet. 2002 Oct;32(2):321-5
12244320
Urology. 2000 Apr;55(4):553-9
10736500
Cancer Res. 2000 Oct 15;60(20):5857-61
11059783
Am J Hum Genet. 2003 Jan;72(1):208-12
12471593
Cancer Res. 2004 Mar 15;64(6):2076-82
15026346